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Albuminuria in Diabetes Mellitus 
Relation to Ambulatory Versus Office Blood 
Pressure and Effects of Cilazapril 
Bernard Waeber, Peter We idmann,  Donald Wohler, and Yves Le Bloch 
This study aimed to investigate the relationship 
between microalbuminuria and office blood 
pressure (BP) as compared with ambulatory BP in 
patients with diabetes mellitus under everyday 
practice conditions. It was also undertaken to 
assess the effect of the angiotensin converting 
enzyme inhibitor cilazapril on diabetes-associated 
albuminuria. Ambulatory BP was recorded uring 
daytime in 54 patients with type II diabetes 
mellitus at the end of a 4-week period during 
which they received no vasoactive drug. The 
difference between office and ambulatory BP was 
unpredictable in the individual patient. There was 
no significant correlation between either 
ambulatory or office BP and urinary albumin/ 
creatinine ratio. Fifty-one patients underwent a 
40-week treatment with 5 mg/day of cilazapril. 
There was, in the absence of satisfactory BP 
control, the possibility of adding the calcium 
antagonist amlodipine (5 mg/day) from the 10th 
week onward and 12.5 rag/day of 
hydrochlorothiazide from the 20th week onward. 
Office mean BP was significantly reduced after 30 
to 40 weeks of therapy in patients with 
normoalbuminuria (n  = 19 ,  -14%, P < .001), in 
those with microalbuminuria (n  = 22, -6.6%, P < 
.01), as well as in those with clinical proteinuria 
(n = 9, -11.4%, P < .01). During the same time, 
the urinary albumin/creatinine ratio was not 
modified in normoalbuminuric patients (n = 19, 
+24.6%, P = .72) as well as in those with clinical 
proteinuria (n = 9, -29.4%, P -- .09). On the other 
hand this value was significantly reduced for the 
group with microalbuminuria (n  = 23 ,  -24.3%, P 
< .05). In the overall population, as well as in 
hyperalbuminuric patients (patients with 
microalbuminuria + patients with clinical 
proteinuria), the reduction of the albumin/ 
creatinine ratio was also significant (n  = 51, -7%, 
P < .01 and n = 32, -25,7%, P < .01, 
respectively). In conclusion, the findings of this 
study performed by practicing physicians how 
that ambulatory BP may differ greatly from office 
BP in diabetic patients. They also indicate that 
urinary albumin excretion is poorly correlated 
with office and ambulatory BP in type lI 
diabetics. Finally, they demonstrate he 
antiproteinuric action of prolonged treatment with 
the angiotensin converting enzyme inhibitor 
cilazapril, whether given alone or combined with 
amlodipine. © 1996 American Journal of 
Hypertension, Ltd. Am J Hypertens 1996;9:1220- 
1227 
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I 
n Europe more than 25 million persons may have 
diabetes mellitus, 10% of them insulin dependent 
(type I) and 90% primary non-insulin-dependent 
(type II) diabetes mellitus. About 35% of type I and 
25% of type II diabetics develop nephropathy. 1 This com- 
plication manifests itself 7 to 15 years after the onset of 
diabetes mellitus (in diabetes mellitus type II seemingly 
earlier) as persistent microalbuminuria (incipient ne- 
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phropathy).-" In its natural course, microalbuminuria 
progresses in 80% to 100% of cases within 10 to 30 years 
from diabetes mellitus onset to proteinuria of >0.3 g /  
day and glomerular filtration rate now begins to decrease 
(clinical nephropathy). And the latter progresses in 90% 
rather rapidly, within 10 years to terminal renal failure. 
Not only has diabetes mellitus emerged as the most com- 
mon cause of end-stage kidney disease, ~but relafive car- 
diovascular mortality is increased up to sixfoM in diabet- 
ics with hypertension and/or  microalbuminuria 4-6 and 
up to a staggering 35-fold once the latter has progressed 
to clinical nephropathy. 7'8 
Diabetes mellitus-associated metabolic hanges and 
glomerular hypertension are thought o promote dia- 
betic nephropathy9 '1° Intraglomerular pressure de- 
pends in part on systemic blood pressure (BP). In dia- 
betes mellitus type I, BP tends to rise slightly, although 
still within the normal range, before or concomitant 
with the onset of incipient nephropathy, u'12 Thus, posi- 
tive correlations between urinary albumin excretion 
and clinic BP have been noted in type I diabetes melli- 
tus. H'1~ In diabetes mellitus type II, systemic hyperten- 
sion often exists already ears before the appearance of
diabetes mellitus or nephropathy. 1't4 Because office BP 
is often distorted by a "'white-coat" pressor effect, am- 
bulatory BP has been found to be more predictive of 
cardiovascular complications ~ -18 and perhaps could 
also correlate better with diabetic albuminuria. 
In reducing microalbuminuria or clinical proteinuria, 
certain angiotensin converting enzyme (ACE) inhibi- 
tors have been more effective than other antihyperten- 
sive agents, t~'2° Considering this state of information, 
which has been based largely on studies performed in 
specialized investigation centers, the present study was 
undertaken to evaluate the following questions: 1) to 
what extent are office BP readings in type II diabetic 
patients with hypertension or microalbuminuria pre- 
dictive of their mean daytime ambulatory BP? 2) what 
is the relationship of type II diabetes mellitus-associated 
albuminuria observed under nonspecialized, everyday 
practice conditions with office BP as compared to am- 
bulatory BP? and 3) what is the efficacy of the newer 
long-acting ACE inhibitor cilazapril in reducing type II 
diabetes mellitus-associated hyperalbuminuria? 
PATIENTS AND PROTOCOL 
Patients were enrolled by their treating physicians in pri- 
vate practice. Men and women, aged 18 to 75 years, with 
type II diabetes mellitus and on standard antidiabetic 
therapy (dietary instruction and oral antidiabetic agents 
or insulin where appropriate) were considered eligible. 
An initial clinical examination including retinoscopy, a 
standard 12-lead electrocardiogram, and measurement of 
urinary albulnin/creatinine ratio in a spot urine were 
performed. Patients who were either diagnosed as 1 ) hy- 
pertensive (based on repeated office BP > 140/90 mm 
Hg and / or the history of ongoing antihypertensive tr at- 
ment), or 2) normotensive (office BP -< 140/90 mm Hg) 
but having an increased urinary albumin excretion (albu- 
min / creatinine ratio < 2.27 mg/mmol  in the spot urine), 
entered the study. 
All these patients underwent a 4-week observation pe- 
riod, during which they received no vasoactive drugs 
( "wash-out" period). During the last 2 weeks, urine spots 
were collected again two to three times for determination 
of albumin / creatinine ratio. The mean of these measure- 
ments was calculated. Office BP, daytime ambulatory BP 
profiles, and various laboratory parameters ( ee below) 
also were determined at the end of the wash-out period. 
The study was subdivided into two parts (Table 1 ). Study 
A comprised all patients in whom at the end of the wash- 
out period ambulatory BP monitoring could be success- 
fully performed and analyzed. The aim of this study part 
was to assess the relationships among ambulatory BP, 
office BP, and albuminuria in type II diabetics off antihy- 
pertensive drugs. The study B examined the effects of the 
active antihypertensive drug therapy on these variables 
and involved all patients exhibiting at the end of the 4- 
week run-in period an elevated ambulatory or, in the 
absence of an interpretable ambulatory profile, office dia- 
stolic BP > 90 mm Hg or confirmed elevated albuminuria. 
Exclusion criteria were severe hypertension (mean am- 
bulatory or office diastolic BP > 115 mm Hg) or malig- 
nant hypertension, secondary forms of hypertension (ex- 
cept hypertension associated with diabetes mellitus per 
se), type I diabetes, decompensated diabetes mellitus, 
proliferative diabetic retinopathy, myocardial infarction, 
congestive heart failure, stroke, nephropathy of nondia- 
betic origin, serum creatinine > 160/lmol/L, kalemia > 
5 mmol / L, pregnancy or lactation, drug or alcohol abuse, 
suspected noncompliance with treatment, and severe ill- 
nesses uch as chronic hepatitis, liver cirrhosis, or cancer. 
The active treatment period lasted 40 weeks. Blood 
pressure was monitored at 10-week intervals at the office 
and whenever possible by ambulatory BP monitoring. 
During the first 10 weeks, the ACE inhibitor cilazapril 
was administered in a dose of 5 mg once daily. During 
weeks 11 to 20, patients with a mean ambulatory diastolic 
daytime BP of < 85 mm Hg or, in the absence of interpret- 
able ambulatory data, an office diastolic BP of -< 90 mm 
Hg continued on cilazapril monotherapy, 5 mg daily, 
whereas patients whose BP was still elevated (according 
to either ambulatory or office BP values) received cilaza- 
pril, 5 mg, combined with the calcium antagonist amlodi- 
pine, 5 mg, once daily. From week 21 to 40, patients who 
at week 20 were normotensive (according to the criteria 
described above) continued their previous medication, 
whereas those who were still hypertensive r ceived in 
addition hydrochlorothiazide, 12.5 mg once daily. Deter- 
minations of urinary albumin/creatinine ratio were per- 
formed at 10-week intervals. The means of measurements 
at the end of the wash-out phase were used as basal 
pretreatment values whereas the mean of measurements 
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TABLE 1. STUDY PROTOCOL AND DEMOGRAPHICS IN TYPE II DIABETICS WITH HYPERTENSION* 
AND/OR HYPERALBUMINURIAt 
Study A Study B 
Inclusion criteria after >4 weeks 
without vasoactive drugs 
Study aim 
Technically satisfactory ambulatory BP 
monitoring 
To assess relationships among ambulatory 
BP, office BP, and albuminuria in type II 
diabetics off vasoactive drugs 
Hypertension* or hyperalbuminuriat 
or both 
To assess effects of 40 weeks of treatment 
with ACE inhibitor cilazapril and, if 
necessary, added amlodipine and 
hydrochlorothiazide, on BP, 
albuminuria, nd some additional 
variables 
Patients completing study: 
No. 54 51 
Age (years) 56 _+ 1.5 57 ÷ 1.4 
Sex distribution (F/M) 15/39 15/3o 
Known duration of diabetes (years) 8.4 - 1.1 9.1 x 1.1 
Body weight (kg) 84.5 _+ 2.2 84.3 _+ 2.3 
ACE, ang~otensm converting enzyme. BP, blood pressure 
* Mean daytm~e ambuhltory diastohc BP >85 mm Hg or seated ot~ce &astohc BP >90 mm Hg; + Urma~ albumm/creatmme ratto >-2.27 rag~retool. 
Data shown as means ± SEM 
after active treatment weeks 30 and 40 were used as final 
values. 
At completion of the run-in phase and again after 10 
and 40 weeks of active treatment, fasting serum glucose, 
glycosylated hemoglobin (HbA~c), fructosamine, total 
cholesterol, HDL cholesterol, triglycerides, odium, potas- 
sium, creatinine, transaminase and alkaline phosphatase 
levels, hemoglobin and white blood cell count were mea- 
sured. Fasting C-peptide for verification of diabetes melli- 
tus type was determined at baseline. At the end of the 
study, clinical examinations, retinoscopy, and standard 
12-1ead electrocardiogram were repeated. 
Analytical Methods Office BP was determined after 
5 min in the seated position by the conventional uscul- 
tatory method using a sphygmomanometer and a pres- 
sure cuff. The fifth sound was defined as diastolic BP. 
Ambulatory BP monitoring was performed with the 
device Profilomat (Disetronic, Burgdorf, Switzerland), 
a fully automated apparatus. This ambulatory recorder 
has been validated according to the protocol of the Brit- 
ish Hypertension Society, receiving the best grade for 
diastolic and the second best grade for systolic BP. 21 
Participating physicians attended preparatory training 
sessions where they were instructed to 1 ) place the cuff 
over the previously palpated brachial artery, 2) always 
take three auscultatory control readings with a sphyg- 
momanometer connected simultaneously to the cuff, 
and 3) systematically validate the method by ascertain- 
ing before each BP monitoring that the average diastolic 
and systolic differences between readings by the re- 
corder and control measurements were < 5 mm Hg. 
The patients were asked to remain motionless during 
the automatic measurements every 30 min during wak- 
ing hours of the day while pursuing their normal activi- 
ties. The arithmetic mean of all daytime measurements 
was calculated and designated as ambulatory BP. Only 
those recordings with at least 75% of the preset daytime 
measurements available for analysis were accepted and 
included in the final evaluation. 
Urinary albumin concentration was measured by the 
immunoturbidimetric method. Using the mean of mea- 
surements at the end of the wash-out phase, normoal- 
buminuria was defined as an albumin/creatinine ratio 
of < 2.27 mg/mmol  creatinine, microalbuminuria asa 
ratio of 2.27 to 22.7 mg/mmol  creatinine, and clinical 
proteinuria s a ratio of > 22.7 mg/mmol  creatinine. 
All laboratory measurements were performed centrally 
by an independent institution (Viollier, Basle, Switzer- 
land). 
Statistical Analysis Data management and analysis 
were performed by an independent company (Brunner 
and Hess, Z~rich, Switzerland). Descriptive statistics 
were based on absolute and relative frequencies, counts 
and mean values with standard deviations for the 
groups and subgroups to be considered, as well as scat- 
ter plots of bivariate distributions with their respective 
regression lines. Calculation of P values for the rejection 
of zero hypothesis was performed with nonparametric 
test procedures (Wilcoxon pairwise and Wilcoxon- 
Mann-Whitney groupwise). Results are presented as 
means + SEM. 
RESULTS 
Part 1: Ambulatory BP, Office BP and Albuminuria 
in the Untreated Patients At the end of the wash-out 
period, an ambulatory BP profile meeting the set quality 
criteria (see above) could be obtained in 54 patients 
(Table 1 ). Mean daytime ambulatory BP averaged 147 / 
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TABLE 2. AMBULATORY OR OFFICE BLOOD PRESSURE AND ALBUMINURIA IN DIABETIC PATIENTS 
Blood Pressure (mm Hg) 
Patients No. Office Ambulatory+ 
Urinary Albumin/Creatinine Ratio 
(mg/mmol) 
All 54 156"/97 __~ 3/2 147/98 _+ 2/2 39 ± 12 
Normoalbuminuria 21 154/99 ± 4/3 145/100 + 4/3 1.3 ± 0.1 
Microalbuminuria 23 155/93 ± 4/2 147/96 + 3/2 8.1 + 1.1 
Clinical proteinuria 10 162/100 ± 4/2 152/100 + 4/3 159 + 39 
Values are means +_ SEM. 
* P < .05 versus ambulatory s stohc blood pressure. 
T Mean of daytime values 
98 -4- 2 / 2 mm Hg and office BP 156 / 97 -- 3 / 2 mm Hg 
(Table 2). Forty-nine patients (91%) were considered 
hypertensive based on ambulatory BP measurements 
(mean daytime diastolic BP, _~ 85 mm Hg) and 37 pa- 
tients (69%) had office hypertension (office diastolic BP, 
> 90 mm Hg). Urinary albumin excretion was normal 
in 21 patients (39%). Twenty-three patients had micro- 
albuminuria (43%) and 10 clinical proteinuria (19%). 
There was no significant difference in ambulatory or 
office BP among these three subgroups. However, sys- 
tolic BP was higher (P < .05 for all patients) when 
measured by a physician than during ambulatory moni- 
toring in patients with normoalbuminuria or microalbu- 
minuria as well as in those with clinical proteinuria. 
The difference between office BP and the mean of 
ambulatory BP was calculated in each patient. Figure 
1 depicts the relationship between this parameter (on 
the ordinate) and the BP reading taken by the physician 
(on the abscissa), both for systolic (upper panel) and 
diastolic (lower panel) BP. The sign of the difference 
between office and ambulatory BP is positive when BP 
is higher in the presence than in the absence of the 
physician, the converse being true when the sign of the 
difference is negative. Despite significant correlations 
between the two parameters for both systolic (r = 0.58, 
P < .001) and diastolic (r = 0.37, P < .01) BP, the 
scatter of the individual values was clearly too large to 
allow the prediction of ambulatory BP on the basis of 
office BP readings. 
Due to a non-Gaussian distribution, the natural oga- 
rithm of urinary albumin / creatinine ratio was used for 
regression analysis. Urinary albumin/creatinine ratio 
was unrelated to either ambulatory or office diastolic 
BP or systolic BP (Figure 2). 
Part 2: Ambulatory BP, Office BP and Albuminuria 
During Active Treatment Sixty-two diabetic patients 
fulfilled the inclusion criteria at the end of the 4-week 
wash-out phase and underwent the protocol of the ac- 
tive treatment period. Eleven of these patients with- 
drew during this phase because of side effects (n = 5), 
non-drug-related intercurrent illnesses (n = 3), antihy- 
pertensive inefficacy (n = 1), or merely at their own 
wish (n - 2). Therefore, 51 patients completed the 
study (Table 1 ) and could be analyzed for efficacy. Six- 
teen patients had previously not received antihyperten- 
sive therapy. Of the remaining 35 patients, 12 had been 
on a fl-blocker, 13 on a diuretic, 13 on an ACE inhibitor, 
5 on a calcium antagonist, and 2 on other agents. These 
drugs, given either as mono- or combined therapy, 
were all withdrawn before the 4-week run-in phase. 
During wash-out conditions, 19 (37%) patients had 
normoalbuminuria, 23 (45%) microalbuminuria, nd 9 
(18%) clinical proteinuria (Table 3). On active treat- 
ment, office BP decreased progressively, although in 
the clinical proteinuria subgroup this was delayed be- 
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FIGURE 1. Difference between office and ambulatory blood 
pressure (Office-Ambulatory BP ) plotted against he correspond- 
ing office blood pressure (upper panel for systolic and lower 
panel for diastolic) in patients with type H &abetes mellitus. 
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ordinate) in patients with type II dmbetes. 
yond the 10th treatment week (Table 3). Compared 
with the wash-out phase, changes in BP after 30 to 40 
weeks of therapy did not differ significantly between 
the albuminuria subgroups. Thus, mean BP( ie, diastolic 
BP + systolic BP + diastolic BP/3)  was lowered from 
120.6 ± 2.8 mm Hg to 103 _+ 1.9 mm Hg (P < .0005, 
-13.5%) in the patients with normoalbuminuria, from 
114.6 ± 2.7 mm Hg to 106.4 ± 1.7 mm Hg (P < .005, 
-6.6% ) in those with microalbuminuria, and from 120.1 
+2.7mmHgto106.3+3.1mmHg(P<.01 ,  11.4%) 
in those with clinical proteinuria. 
Considering subgroups with different drug treat- 
ments, mean BP decreased in the cilazapril mono- 
therapy group (n = 14), representing 28% of pa- 
tients, from 114.3 ± 2.7 mm Hg after wash-out to 
102.7 + 2.8 mm Hg (P < .01, -9 .6%) after 30 to 40 
weeks of active therapy. In the ACE inhibitor cal- 
cium antagonist group (n = l l  ), accounting for 22% 
of the patients, mean BP was not improved after the 
initial 10 weeks of cilazapril monotherapy (117.2 _+ 
3.3 mm Hg v. 118.5 ± 2.4 mm Hg after wash-out) ,  
but decreased to 105.0 _+ 2.4 mm Hg (P < .01, -10%) 
at the end of the subsequent c i lazapr i l -amlodip ine 
combination phase. In the triple therapy group (n = 
17), mean BP tended to decrease only minimal ly 
after the initial cilazapril monotherapy (from 124.1 
± 3.6 mm Hg to 117.2 + 3.3 mm Hg),  averaged 113.5 
± 2.3 mm Hg (P < .005, -8 .1%) after the subsequent 
10-week c i lazapr i l -amlodip ine combination phase 
and decreased further to 108.2 ± 1.4 mm Hg (P < 
.0005, -7 .8%) after the addit ion of hydrochlorothia-  
zide. 
With regard to heart rate and body weight, no 
significant difference was observed at baseline be- 
tween the three groups, and no significant change 
was seen later during the course of the study (not 
shown).  
Compared with the wash-out phase, active treat- 
ment did not modify the ur inary a lbumin/creat i -  
nine ratio in initially normoalbuminur ia  patients (n 
= 19 ), but distinctly reduced this variable in patients 
with microalbuminuria (n = 23, P < .05, on average 
-24.3 ± 8% at treatment weeks 30 to 40). In those 
with clinical proteinuria (n = 9), the reduction 
( -29.4% ) was highly variable from patient o patient 
and did not achieve a significant level. In all hyperal- 
buminuric patients taken together (n = 32), the re- 
duction achieved -25.7% (from 54 -- 18 mg/mmol  
to 40 + 16 mg/mmol ,  P < .005) (Table 3). 
Considering roups with different drug treatments, the 
urinary albumin / creatinine ratio in the patients receiving 
cilazapril monotherapy (n = 14) decreased from 12.3 + 
5,9 mg/mmol  during wash-out o 9.5 ± 4.8 mg/mmol  
(-22.8%) at treatment weeks 30 to 40 (P = not signifi- 
cant). In the ACE inhibitor calcium antagonist combina- 
tion group (n = 11 ), urinary albumin/creatinine ratio 
decreased from 43.6 ± 31.1 mg/mmol  during wash-out 
to 28.7 + 17.7 mg/mmol  (-34.1%) after the initial 10 
weeks on cilazapril alone, and decreased further to 15.8 
± 8.2 mg/retool  (-63.7%) during the subsequent cilaza- 
pril-amlodipine combination phase. In the triple therapy 
group (n = 17), the urinary albumin/creatinine ratio 
decreased from 60.5 + 29 mg/n~nol  to 47.9 ± 23.4 mg/  
mmol (-20.8%) within the initial 10 weeks of cilazapril 
therapy, but returned to 57.2 ± 30 mg/mmol  (-5.4%) at 
completion of the trial. 
After 30 to 40 weeks of active therapy, there was no 
significant correlation between urinary albumin/creati- 
nine ratio and mean systolic ambulatory BP (r = 0.01 ), 
and systolic office BP (r = 0.01 ). The same was true for 
diastolic ambulatory and office BP (r = 0.02 and r = 0.02, 
respectively). Treatment-associated p rcentage changes 
in urinary albumin / creatinine ratio did not correlate sig- 
nificantly with concomitant changes in mean ambulatory 
and office systolic BP (r = 0.31 and r = 0.01, respectively), 
as well as with changes in ambulatory and office diastolic 
BP (r = -0.08 and r = 0.19, respectively). 
The effects of active treatment on humoral parame- 
ters are shown in Table 4. No significant change was 
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TABLE 3. EFFECT OF ACTIVE TREATMENT ON OFFICE BLOOD PRESSURE (mm Hg) AND URINARY 
ALBUMIN/CREATININE RATIO (mg/mmol) 
Active Treatment 
No. Baseline Week 10 Week 20 Weeks 30-40 
Blood pressure 
Patients with: 
Normoalbuminuria 19 157/102 ± 4/3 
Microalbuminuria 23 154/ 95 + 5/2 
Clinical proteinuria 9 163/ 99 + 5/2 
Urinary albumln/creatinine ratio 
Patients with: 
Normoalbuminuria 19 1.2 _+ 0.1 
Microalbuminuria 23 7.1 + 1.0 
Clinical proteinuria 91 171 ± 48 
142/94 ± 5/3(:~/t) 
147/88 + 4/2(*/t) 
161/99 ± 7/3(NS/NS) 
1.4 + 0.2(NS) 
6.4 ± 1.3(NS) 
127 ± 35 (NS) 
137/89 ± 4/3(~/~) 
141/90 ± 3 /4( t / t )  
146/92 + 5/3(*/*) 
1.6 ± 0.2(NS) 
4.7 ± 0.8(t) 
143 ± 55 (NS) 
137/88 + 3/2(~/$) 
147/86 ± 4/2(*/~:) 
144/88 + 6/3(~/t) 
1.4 ± 0.2(NS) 
5.4 _+ 1.0(*) 
128 + 48 (NS) 
* P < .05: t P < Ol; ~. P < .OOl, NS = mmslgmficant versus basehne 
Values are means + SEM. 
observed ur ing  the course of the study in pat ients with 
normoa lbuminur ia  as wel l  as in those with microalbu-  
minur ia  or clinical proteinur ia.  There were also no sig- 
nif icant changes in the treatment groups,  except for a 
sl ight increase in serum glucose on hydrochloroth ia-  
z ide-conta in ing tr iple therapy (10.68 _+ 0.84 mmol  / L v 
9.19 + 0.69 mmol /L  after washout ,  P < .05). 
Five pat ients d iscont inued the s tudy because of ad-  
verse symptoms such as dry  cough (n = 3), a rash 
appear ing  dur ing  the ci lazapri l  monotherapy  phase (n 
= 1), or t i redness and depress ion reported dur ing  the 
c i lazapr i l -amlod ip ine  combinat ion phase (n = 1). 
Intercurrent  diseases, leading to s tudy discont inua-  
tion but  rated as drug  unrelated,  inc luded myocard ia l  
infarction, k idney tumor,  and amputat ion  of a foot, each 
in 1 patient.  
DISCUSSION 
The f ind ings of this s tudy  demonst ra te  that in type II 
d iabet ic  pat ients  w i th  hyper tens ion  and/or  hypera l -  
buminur ia ,  large d i f ferences exist between BP mea-  
sured  in the phys ic ian 's  office and  mean dayt ime am- 
bu la tory  BP, and that the scatter of ind iv idua l  va lues  
of both systol ic and d iasto l ic  BP was c lear ly too large 
to a l low the pred ic t ion  of ambulatory  BP on the basis 
of office BP readings.  Moreover ,  contrast ing wi th  the 
known close corre lat ion between ur inary  a lbumin  ex- 
cret ion rate and systemic arter ia l  BP in d iabetes  mel l i -  
tus type I, 11'13 the level  of a lbuminur ia  in 54 type II 
d iabet ics  rece iv ing no ant ihyper tens ive  therapy  was  
found to be unre la ted  to e i ther office or ambulatory  
BP. Complement ing  this, t reatment  wi th  the ACE in- 
h ib i tor  c i lazapr i l  a lone or combined  wi th  amlod ip ine  
improved both hyper tens ion  and hypera lbuminur ia .  
The presence of d iabetes  mel l i tus  combined  w i th  
hyper tens ion  or hypera lbuminur ia  represent  a very  
h igh r isk s i tuat ion.  4 s Therefore,  d iabet ic  pat ients  de-  
serve careful  eva luat ion  and mon i tor ing  of their  BP 
and a lbuminur ia  state. This tr ial was per fo rmed by  
pract ic ing phys ic ians ,  thus ref lect ing c losely the expe-  
TABLE 4. EFFECTS OF ACTIVE TREATMENT ON HUMORAL PARAMETERS 
Clinical 
Normoalbuminuria Microalbuminuria Proteinuria All  Patients 
Glycosylated hemoglobin (%) 
Serum fructosamine (#tool/L) 
Serum glucose (retool/L) 
Serum creatinine (pmol/L) 
Serum cholesterol/HDL 
Serum, triglycerides (retool/L) 
Before 6.9 + 0.3 7.5 + 0.3 7.2 ± 0.4 7.3 _+ 0.2 
After 6.8 ± 0.4 7.7 + 0.4 7.7 + 0.3 7.4 + 0.2 
Before 293 + 16 315 _+ 113 77 ± 18 300 + 9 
After 278 + 14 319 + 14 285 ± 17 299 + 9 
Before 8.6 ± 0.6 10.0 ÷ 0.7 10.8 ± 1.3 9.5 ± 0.5 
After 9.3 + 0.7 %8 -- 0 7 10.3 + 1.2 9.7 + 0.5 
Before 89 ± 3 q2 ± 4 94 _+ 4 96 ± 2 
After 85 + 2 93_+4 96 = 2 91 ± 2 
Before 4.2 ± 0.4 4.8 ÷ 0.3 5.8 ± 1.0 4.8 _+ 0.3 
After 4.2 ± 0.4 4.7 _+ 0.3 5.5 ÷ 0.8 4.7 ± 0.3 
Before 2.0 + 0.3 2.0 +_ 0.3 3.3 ± 1.1 2.3 ± 0.3 
After 2.2 + 0.5 2.6 + 0.6 4.7 + 2.0 2.q + 0.5 
Means +_ SEM. 
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rience accumulated by most doctors in taking care of 
diabetic patients. Moreover, complementing the con- 
ventional BP measurements by the physician, BP dur- 
ing everyday activities was monitored whenever pos- 
sible using the ambulatory recorder Profilomat. This 
fully automated device is known to provide accurate 
BP profiles. 21 A large body of evidence suggests that 
BP recorded outside the medical setting correlates bet- 
ter with renal, cardiac, and cerebral injury than BP 
obtained sporadically by a physician. 15-1s'22'23 There- 
fore, the use of ambulatory BP monitoring seems par- 
ticularly attractive in diabetic patients. 
The pathogenesis of hyperalbuminuria as a char- 
acteristic although not specific manifestation of mi- 
crovascular renal disease is thought o involve he- 
reditary, metabolic, and hemodynamic factors. 9'1°'24"25 
Intraglomerular p essure and flow, rather than sys- 
temic BP, is the ultimate hemodynamic determinant of 
glomerular damage. 1°Therefore, the tendency for a 
close albuminuria-BP relationship in untreated type I 
diabetics1113.22 and the lack of such a correlation i  type 
II diabetics, suggests a different impact of systemic BP 
on intraglomerular pressure. Thus, in diabetes mellitus 
type I, where systemic BP increases lightly before or 
at the onset of nephropathy, afferent arteriolar vasodi- 
lation may allow even such mild systemic BP changes 
to produce parallel increases in intraglomerular p es- 
sure. In contrast, in type II diabetics arterial hyperten- 
sion often precedes diabetes mellitus or nephropa- 
thy, 14,a6 but may have a less direct effect on intraglomer- 
ular pressure. Regardless of the exact systemic- 
intrarenal pressure relationships, increases in systemic 
BP are likely to promote, although not necessarily initi- 
ate, hyperalbuminuria and nephropathy progression i
diabetes mellitus type I as well as type [I. 2,27 
The antiproteinuric efficacy of antihypertensive 
drugs has been shown to differ among certain agents 
or drug classes. 19'2° Thus, an antiproteinuric effect of 
diuretics, fl-blockers, and several calcium antagonists 
(except nifedipine, which is ineffective) requires a 
concomitant reduction in systemic arterial BP. In con- 
trast, ACE inhibitors exert direct intrarenal effects 
and, thereby, reduce proteinuria even at an un- 
changed systemic BP. By inhibiting angiotensin II gen- 
eration they dilate preferentially the efferent arteriole, 
thereby decreasing intraglomerular pressure to a level 
lower than expected from changes in systemic BP per 
se; moreover, they decrease the glomerular permeabil- 
ity for proteins. 28 Therefore, ACE inhibitors have 
emerged as the preferred rugs for treating microal- 
buminuria or clinical proteinuria in diabetic pa- 
tients, t4 The 26% albuminuria reduction achieved 
with cilazapril in the hyperalbuminuric diabetics is 
quite similar to the previously reported efficacy of 
captopril in doses of 75 to 100 mg/day  in type I dia- 
betics with either incipient or clinical nephropa- 
thy. 2~'3~ In type II diabetics, long-term treatment with 
enalapril reduced the progression from incipient o 
clinical nephropathy in normotensive as well as in 
hypertensive patients 31,32; moreover ,  in the normoten- 
sive diabetics, microalbuminuria w s not lowered but 
rather stabilized by enalapril, whereas it increased 
progressively on placebo. 3~ Because cilazapril also 
lowered systemic BP, the relative contribution of the 
latter versus direct intrarenal actions could not be fur- 
ther dissected. In the group of diabetics whose BP was 
not controlled satisfactorily after 10 weeks of cilaza- 
pril monotherapy, 20 weeks of combined treatment 
with cilazapril and the calcium antagonist amlodipine 
further decreased albuminuria from -34% to -64%. 
This complements the previous observation of an ad- 
ditive antiproteinuric action of lisinopril and diltia- 
zem versus verapami133"34 and supports the potential 
usefulness of certain ACE inhibitor calcium antago- 
nist combinations in the treatment ofdiabetic patients 
with hypertension and/or  hyperalbuminuria. 14"34 
Proteinuria is most likely not an innocent by- 
stander, but may probably per se promote nephropa- 
thy progression 35'36 and therefore, requires treatment. 
Without effective therapy, in 80% to 100% of patients 
diabetic microalbuminuria will progress to the high- 
risk state of clinical nephropathy. 2'9 Most important, 
slowing of diabetic nephropathy progression oc- 
curred subsequent to proteinuria reduction, but has 
never been described with persisting unchanged pro- 
teinuria. 
Overall, the different antihypertensive drugs used 
in the present rial were well tolerated. Only five pa- 
tients interrupted the treatment because of side ef- 
fects. The therapy had no unfavorable impact on hu- 
moral parameters. 
In summary, these data demonstrate he antipro- 
teinuric effect of prolonged ACE inhibition with cila- 
zapril in diabetic patients. They also indicate that in 
type II diabetics, urinary albumin excretion is poorly 
correlated with BP, whether measured in the physi- 
cian's office or recorded in the patient's usual environ- 
ment. Moreover, it appears that the level of diastolic 
BP is underestimated in some diabetics when the mea- 
surement is performed by a physician. Finally, the 
results how that ambulatory BP cannot be predicted 
in the individual diabetic patient based on office BP 
readings. 
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